It has been demonstrated that an antibody–drug conjugate (ADC) targeting TF-expressing tumor cells, called ICON-1, selectively kills TF-expressing tumor cells in vitro and inhibits tumor growth in vivo [13, 22–26]. The gene discussed is TF; the disease is neoplasm.